Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GCLC | P48506 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585268 | 1.00 | APOBEC3A (0.36) | APOBEC3AAPOBEC3GACEPMP22SIGMAR1 | |
| SCHEMBL13584558 | 0.95 | PMP22 (0.39) | ACEPMP22POLBKMT2AGCLC | |
| SCHEMBL13584559 | 0.95 | PMP22 (0.39) | ACEPMP22POLBKMT2AGCLC | |
| SCHEMBL13585327 | 0.90 | PMP22 (0.39) | ACEPMP22KMT2AGCLCTBXAS1 | |
| SCHEMBL13585323 | 0.90 | PMP22 (0.39) | ACEPMP22KMT2AGCLCTBXAS1 | |
| SCHEMBL1768934 | 0.87 | DPP7 (0.40) | ACEPMP22KMT2AGCLCTBXAS1 | |
| SCHEMBL1768936 | 0.87 | DPP7 (0.40) | ACEPMP22KMT2AGCLCTBXAS1 | |
| SCHEMBL1768846 | 0.86 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GPMP22SIGMAR1POLB | |
| SCHEMBL1768848 | 0.86 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GPMP22SIGMAR1POLB | |
| SCHEMBL13585220 | 0.86 | DPP7 (0.42) | ACEPMP22KMT2AGCLCTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | APOBEC3A 3699/4885APOBEC3G 3885/4885ACE 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.